Some of the names on the move ahead of the open.» Read More
Merck shares rose sharply Friday after the drugmaker raised its outlook for first-quarter and full-year earnings, citing strong sales across its range of products, and said a federal court judge dismissed a class-action securities lawsuit against the company.
Merck's new pain reliever drug Arcoxia, which was proposed as a successor to Vioxx, was rejected by a federal health advisory panel. A Food and Drug Administration drug safety expert earlier told the panel that the drug may increase substantially the risk of stroke and heart attack and is no more effective for pain relief than other medicines in the same class.
Since another pharmaceutical industry blog has already posted an item about this under the title, "Son of Vioxx...." and since I don't want to be accused of plagiarism or sexism I've opted for "Daughter of Vioxx".
Mylan Laboratories raised its fiscal 2007 earnings forecast, citing the strong performance of its generic drugs business, pushing its shares up as much as 4%.
The AFL-CIO, the largest U.S. union federation, is targeting Verizon Communications in a campaign against high executive pay, and will vote against the company's compensation committee at the company's May 3 annual meeting.
Despite a volatile first quarter, stocks aren't much above where they were at the beginning of the year. But even if the major averages aren't showing big gains, smart investors know where to look for growth opportuntities.
So it was the second night of Passover and I was driving to a seder in New Jersey Tuesday evening when I get the call. My producer, Ruth, said she'd just heard at approximately 6 p.m. ET from a Pfizer spokesman who told her that a front page article in "USA Today" (which had been on newsstands and on the web since early that morning) contained an error:
Britain's consumer affairs watchdog said on Wednesday it would investigate the U.K. market for distributing medicines after drugs giant Pfizer struck a deal to sell its products through a single wholesaler.
Iranian mischief is the single most bankable trend in the world, Cramer says. So he’s got a doomsday portfolio for you just in case events take a turn for the worst. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Ads for Pfizer Inc.'s Celebrex arthritis drug are set to splash across U.S. television screens on Monday after more than a two-year hiatus, with an unusual upfront focus on its risks rather than its benefits.
Embargo-gate at the ACC Scientific journals and medical groups employ media embargoes on studies that are to be published or presented. The common practice gives reporters like me a chance to read and digest the information in advance, interview researchers and experts, maybe talk to patients so that when the embargo lifts full and accurate stories will air, run in the papers or cross the wires. It also gives the journals and medical groups a way to manage the news cycle and get more media bang for their publication or conference. Such was supposed to be the case at this week's American College of Cardiology conference in New Orleans.
Stocks ended mixed as the major markets bounced off the day's lows following disappointing monthly housing data. "We may see some weakness, but overall we like the market. I think the direction is going to be higher," said Sebastian Leburn, chief investment officer at Weiss Capital Management, in an interview with CNBC.com.
Merck and Schering-Plough said on Monday they were beginning development of a cholesterol-lowering product that would combine their Zetia drug with Pfizer's Lipitor.
Pfizer's abandoned experimental drug torcetrapib failed to slow clogging of heart arteries even as it boosted "good" cholesterol levels, according to a study presented Monday.
Stocks closed near the unchanged mark as investors pulled money out of the tech sector and moved into energy stocks. "With the recent volatility that we've had, investors are taking a closer look at their portfolios and they're a little more cautious," said Ron Papanek, a strategist with RiskMetrics Group.
The decision bars Teva from launching a competitor drug in the U.S. until December 2015, Pfizer said.
We're gearing up for a busy few days on the beat starting Friday. That's when biotech giant Genentech holds its annual analyst meeting in New York City. We'll be there. Last year the company put out new, boosted financial guidance in the middle of the trading day and it moved the stock. CEO Art Levinson told the crowd of analysts he liked to time it that way so they'll stick around for the whole day.
Last night I debated John Challenger of Challenger, Gray and Christmas, the firm that each year comes out with that March Madness lost wages study.
In a matter of seconds, Cramer lambastes three callers' stocks. Sometimes the truth hurts.